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in co-culture with rat cardiomycytes. Spontaneous beating of ASCs was most pro-
nounced when there was cell-cell contact with rat CMCs. While all of the non-red cells
with typical rat CMC morphology stained positive for cardiac-specific alpha-actinin, few
fluorescent ASCs were also positive for cardiac-specific alpha-actinin.
Conclusions: Our experiments suggest that human subcutaneous adipose tissue con-
tains cells which in culture express the stem cell marker CD34 and have potential to
acquire a cardiomyocyte phenotype. Considering that large quantities of fat can be easily
harvested from patients, cell therapy using autologous ASCs for cardiac regeneration or
repair may represent a novel therapeutic option for patients with cardiomyopathy.
1068-127 Ischemic Precondition Improves Performance of the 
Hearts With Coronary Delivery of Embryonic Stem 
Cells: Assessment by a Langendorff Perfusion Model
Jing Lin, Shu Li, Eric Lenehan, Mitra Rajabi, Rosalinda Madonna, Corina Rosales, 
James T. Willerson, Yong J. Geng, The University of Texas Medical School at Houston, 
Houston, TX, Texas Heart Institute, Houston, TX
Background: Intracoronary stem cell perfusion is a novel therapy for heart failure. How-
ever, concern has been raised about the biosafety of this therapy. This study aimed at
analyzing functional and metabolic alterations in the hearts perfused with embryonic
stem cells (ESCs).
Methods: Hearts of C57BL/6J mice were perfused with modified Krebs-Henseleit buffer
on a Langendorff device. Ischemia-preconditioning (IPC) was performed. Thereafter, flu-
orochrome tagged murine D3 ESCs were transfused and hemodynamic parameters,
e.g., coronary flow (CF), heart rate (HR), left ventricular peak pressure (LVP), +dp/dtmax,
and -dp/dtmax, were recorded. Coronary effluents were collected to determine cardiac
troponin I (cTnI). After perfusion, the hearts were fixed and subjected to histopathological
studies. 
Results: Murine hearts with coronary ESC perfusion at 106 cells/ml/min or less showed
no major changes in contractility and rhythm. However, with cell concentration increase
(2.5 ~ 5 x 106 cells/ml/min), the hearts were dysfunctional, with declines in all hemody-
namic parameters and marked increase in cTnI in coronary effluents. Interestingly, IPC
significantly reduced the adverse impact of high ESC perfusion by nearly 50% compared
to heart perfusion without IPC. Improved morphology occurred in IPC myocardium with
ESC perfusion.
Conclusions: Perfusion of ESC at high concentrations may cause cardiac dysfunctions.
IPC may increase tolerance to stem cell perfusion and improve performance of the
hearts.
1068-128 Ranolazine Inhibits Late Sodium Current in Isolated Left 
Ventricular Myocytes of Dogs With Heart Failure
Albertas I. Undrovinas, Nidas A. Undrovinas, Luiz Belardinelli, Hani N. Sabbah, Henry 
Ford Heart and Vascular Institute, Detroit, MI, CV Therapeutics, Palo Alto, CA
Background: We recently reported the existence of novel, ultraslow late sodium current
(INaL) in left ventricular (LV) myocytes isolated from failing human and dog hearts. Aug-
mented INaL has been implicated in ventricular repolarization abnormalities in chronic
heart failure (HF). In the present study we sought to determine the effects of ranolazine
(RAN), a novel anti-ischemic drug, on peak (INaT) and late INaL, action potential (AP)
duration (APD), and early afterdepolarizations (EAD’s) in LV myocytes isolated from dogs
with chronic HF.
Methods: Experiments were carried out in mid-myocardial LV myocytes isolated from the
hearts of 6 dogs with chronic HF produced by the intracoronary microembolization. AP’s
were recorded using the β-escin perforated patch method at a frequency of 0.5 Hz and
35oC. Both INaT and INaL were recorded by a conventional whole-cell patch-clamp tech-
nique. Amplitude and decay of INaL were measured at 200 ms after the onset of a 2 sec-
ond-long depolarization to -30 mV at 0.1 Hz.
Results: RAN, at a concentration of 5 µmol/L, reversibly shortened the APD from a base-
line value of 556 ± 53 ms to 316 ± 34 ms (mean ± SEM, n=8 cells, P<0.05). RAN also
decreased APD dispersion and suppressed EADs. At the same concentration (5 µmol/L),
RAN shifted the mid-point steady-state availability of INaL by -7.7±1.2 mV (n=5 cells). The
potency (IC50 value) of RAN to cause resting block of INaL, assessed by a single-site
binding model, was 6.7 µM (n=6 cells). In contrast, 5µmol/L of RAN did not significantly
inhibit INaT. The IC50 for inhibition by RAN of INaT was 244 µmol/L (n=14 cells). RAN did
not affect the decay time course of INaL.
Conclusion: In these experimental conditions, RAN is approximately a 36-fold more
potent blocker of late INa than peak INa, and reverses the ventricular repolarization abnor-
malities (APD prolongation and EADs) of failing myocytes. These findings suggest that
ranolazine, by inhibiting INaL, may suppress ventricular arrhythmic activity associated
with augmented INaL during repolarization of the action potential in HF.
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1069-105 50-Year Heart Failure Mortality for England and Wales
Steven Sutcliffe, Des Watson, Charles Phillips, Christopher Davidson, Brighton and 
Sussex Universities Hospital, Brighton, United Kingdom
Aim: To analyse heart failure mortality trends for England and Wales over fifty years, from
1951 to 2000.
Design: A retrospective observational study using death certificate and population data
from the Office for National Statistics for England and Wales.
Results: Unadjusted heart failure deaths rose by 3.3 from approximately 3400 in 1951 to
11400 in 1974. Since then, heart failure deaths have fallen by approximately 25% to 8600
in 2000. Throughout this period, the number of people in the Western world surviving
beyond 70 years has steadily increased and so it would be expected that the number of
heart failure deaths would increase too. However, even when heart failure mortality is
standardised to allow for changes in the age, sex and size of the population, there was
approximately a 2.2 rise in mortality from 1951 to the mid-70’s and since then, there has
been a substantial and sustained decline in mortality of approximately 55% by 2000. The
unadjusted female heart failure death rate has been between 1.5 and 2 times that of
males since the early 70’s. However, this higher mortality rate is much less marked when
the differences between the age distribution and sizes of the male and female popula-
tions are taken into account. When compared with trends in mortality for coronary artery
disease the changes with time and by age group are remarkably similar.
Conclusion: The trends in heart failure mortality for England and Wales over 50 years
may reflect genuine changes in disease incidence, influenced by current changes in life-
style and the medical management of cardiac disease. These changes are similar to
those seen in coronary artery disease. The data available cannot estimate the absolute
incidence of deaths involving heart failure because of death certificate completion and
the trends in heart failure diagnosis over time.
1069-106 Deaths From Heart Failure in the Era of the Implantable 
Defibrillator
Jeffrey J. Teuteberg, Usha Tedrow, Eldrin F. Lewis, Anju Nohria, Sui W. Tsang, James C. 
Fang, Michael Givertz, John A. Jarcho, Gilbert H. Mudge, Kenneth L. Baughman, Lynne 
W. Stevenson, Brigham and Women's Hospital, Boston, MA
Background: Despite the growing number of indications for implantable cardioverter-
defibrillators (ICD) and the improving survival with heart failure (HF), morbidity and mor-
tality from progressive HF remain substantial.
Methods: To determine the prevalence of ICDs in patients dying with advanced symp-
tomatic HF, we reviewed all of the patients followed in the HF program with an ejection
fraction (EF) less than or equal to 35% and recent NYHA class III/IV symptoms who died
in the hospital or after discharge with hospice between 1/1/00 and 9/1/03.
Results: There were total of 126 deaths, of which 68 (54%) met the criteria for entry into
the study (57 patients died in the hospital, 9 patients died in hospice). Patients had HF for
a mean of 5.8 years, had a mean age of 61 years, and 75% were men. The mean EF was
19% and moderate to severe right ventricular dysfunction was present in 62%. Beta-
blockers and/or amiodarone were taken by 75% of patients. Ischemic cardiomyopathies
(CM) accounted for 55% of patients, of whom 79% had prior bypass. The mean of the
worst laboratory values in the last six months of life include a sodium of 127, blood urea
nitrogen of 97 and creatinine of 3.7.
Of the 68 deaths, 34 (50%) had an ICD, three of whom also had biventricular pacing. The
prevalence of ICDs was 47% in patients with ischemic CM and 53% in patients with
nonischemic CM. Advance directives specified limits on resuscitation in 24 (71%), of
which 13 (54%) had defibrillation inactivated (10/22 in hospital, 3/3 in hospice), but only a
median of 1 day prior to death. Overall, the ICDs were implanted a median of 21.5
months (range 1-144) prior to death, but 11 (32%) were implanted less than 1 year before
death and 6 (18%) less than 6 months before death (5/6 of these were implanted for pri-
mary prevention).
Conclusions: In patients with advanced HF, there is a high prevalence of ICDs, regard-
less of the etiology of HF. However, the benefit from preventing sudden death may be
diminished as the likelihood of terminal hemodynamic deterioration increases. Therefore,
management of ICDs will become an increasingly important aspect of care at the end of
life.
Table 1. Hemodynamic and Biochemical Alterations at 30 minute after Stem Cells 
Perfusion
ESC Perfusion without IPC
( X 106 cells/ml/min)
ESC Perfusion 
with IPC
( X 106 cells/ml/
min)
0 1.0 2.5 5.0 5.0
CF -10.8
+ 7.2%
-22.2
+ 28.0%
-55.0
+ 32.2%
-63.6
+ 29.7%
-31.4
+ 16.7%
HR -10.2
+ 11.8%
-22.4
+ 24.5%
-19.4
+ 23.7%
-49.7
+ 22.0%
-24.9
+ 10.3%
LVP -1.9
+ 20.7%
-7.0
+ 19.1%
-30.7
+ 24.5%
-50.2
+ 39.0%
-24.4
+ 32.9%
+dp/dt +2.6
+ 15.7%
-7.6
+ 41.3%
-40.4
+ 27.0%
-57.6
+ 36.3%
-32.8
+ 25.1%
-dp/dt -12.8
+ 22.3%
-26.0
+ 24.8%
-50.9
+ 23.5%
-69.1
+ 29.8%
-45.2
+ 20.8%
cTnI +20.9
+ 67.7%
+42.6
+ 70.8%
+256.6
+ 93.1
+1403.4
+ 849.9%
+6.9
+ 20.5%
